Surgical Data Support Nivolumab Plus Chemotherapy for Resectable NSCLC
The neoadjuvant regimen showed higher rates of definitive surgery and minimally invasive approach.
All articles by Leah Lawrence
Less Pain, Fewer Complications With VATS vs Open Surgery in Early-Stage Lung Cancer
Quality of life outcomes were superior with video-assisted thoracoscopic surgery.
Radiotherapy and Surgery Produce Comparable Outcomes in Operable Stage IA Non-Small Cell Lung Cancer
Survival results were similar with stereotactic ablative radiotherapy and surgery.
Clinicians Should Consider EVALI in Patients With a History of Vaping
Despite California’s legal cannabis market, 75% of products that contained THC were obtained from informal sources.
Pulmonary Function Impairments May Increase Lung Cancer Susceptibility
Certain immune-mediated pathways may facilitate pulmonary impairment and lung cancer etiology.
Entrectinib May Eventually Be an Option for ROS1 Fusion-Positive NSCLC
Disease control with entrectinib was found to be active and durable in ROS1 fusion-positive NSCLC.
Ceritinib Plus Nivolumab in NSCLC Characterized by an ALK Mutation
Among patients who were naive to ALK inhibition, the overall response rate was 83% for the 450-mg dose and 60% for the 300-mg dose.
Efforts Made in the 1960s to Curb Smoking Will Have Effects Well Into Future
Scientific models project a continued decrease in lung cancer mortality.
Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer
Significant improvements were seen with the addition of atezolizumab to CnP in stage IV non-squamous non-small cell lung cancer, regardless of patient PD-L1 status.
Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC
Researchers investigated whether the rates of immune-related adverse events linked to treatment with nivolumab or pembrolizumab were similar across 2 different cancer types.
- Loading...
Loading...
Next post in Lung Cancer
Loading... 
Loading...